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Abstract 101 
Clinical trial results have recently demonstrated that inhibiting inflammation by targeting the 102 
interleukin-1b pathway can offer a significant reduction in lung cancer incidence and mortality, 103 
highlighting a pressing and unmet need to understand the benefits of inflammation-focused lung 104 
cancer therapies at the genetic level. While numerous genome-wide association studies (GWAS) 105 
have explored the genetic etiology of lung cancer, there remains a large gap between the type of 106 
information that may be gleaned from an association study and the depth of understanding 107 
necessary to explain and drive translational findings. Thus, in this work we jointly model and 108 
integrate extensive multi-omics data sources, utilizing a total of 40 genome-wide functional 109 
annotations that augment previously published results from the International Lung Cancer 110 
Consortium (ILCCO) GWAS, to prioritize and characterize single nucleotide polymorphisms 111 
(SNPs) that increase risk of squamous cell lung cancer through the inflammatory and immune 112 
responses. Our work bridges the gap between correlative analysis and translational follow-up 113 
research, refining GWAS association measures in an interpretable and systematic manner. In 114 
particular, re-analysis of the ILCCO data highlights the impact of highly-associated SNPs from 115 
nuclear factor-κB signaling pathway genes as well as major histocompatibility complex mediated 116 
variation in immune responses. One consequence of prioritizing likely functional SNPs is the 117 
pruning of variants that might be selected for follow-up work by over an order of magnitude, 118 
from potentially tens of thousands to hundreds. The strategies we introduce provide informative 119 
and interpretable approaches for incorporating extensive genome-wide annotation data in 120 
analysis of genetic association studies. 121 
Keywords: genome-wide annotation, integrative omics, lung cancer, major histocompatibility 122 
complex 123 
 7 
Main Text 124 
1 Introduction 125 
Genome-wide association studies (GWAS) have successfully identified many genetic loci 126 
associated with lung cancer, however it is often difficult to explain exactly how associated 127 
variants perturb biological processes and increase risk of disease (Edwards, Beesley, French, & 128 
Dunning, 2013; Tam et al., 2019). Such difficulties arise in part from a conventional focus on 129 
only a few data types - for instance, genotype or gene expression data - which may naturally 130 
limit our understanding of the processes involved in carcinogenesis. Recently, many quantitative 131 
tools such as fine-mapping have been applied to better prioritize single nucleotide 132 
polymorphisms (SNPs) implicated in lung cancer (Ferreiro-Iglesias et al., 2018), but these 133 
approaches are also generally applied to only a few types of data. Less effort has been focused on 134 
cogently integrating the dozens of multi-omic annotations that offer a range of distinct 135 
perspectives regarding the mechanistic roles of individual SNPs (ENCODE Project Consortium, 136 
2012; Visscher et al., 2017) associated with lung cancer.  137 
 138 
This paper integrates forty different genome-wide variant functional annotations in a generalized 139 
linear mixed model (GLMM) based approach to prioritize and characterize inflammatory- and 140 
immune-related risk SNPs identified by a large-scale GWAS of lung squamous cell carcinoma 141 
(SCC) recently conducted by the International Lung Cancer Consortium (ILCCO) (McKay et al., 142 
2017). Functional annotations describe characteristics of SNPs in a manner that parallels the way 143 
covariates describe subjects in a traditional GWAS regression analysis; one example of an 144 
annotation is the distance (in bp) between a SNP and the nearest transcription start site. The 40 145 
annotations we use can thus be thought of as 40 covariates describing each SNP. In contrast to 146 
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association-based methods such as fine-mapping, our model utilizes genome-wide annotation 147 
data from a variety of modalities to predict the biological roles of a SNP. The multi-dimensional 148 
functional prediction recognizes that different types of variants can possess vastly different 149 
consequences and thus allows SNPs to be evaluated on a range of attributes. This crucial feature 150 
distinguishes the model from other aggregation algorithms, most of which produce a single 151 
composite score that may be difficult to interpret and can over- or under-weight certain traits 152 
based on factors such as the type of training data used (Huang, Gulko, & Siepel, 2017; Kircher et 153 
al., 2014; Rogers et al., 2018).  154 
  155 
Our re-analysis of the previously published ILCCO GWAS data – which reported a table of over 156 
21,000 highly-associated (i.e. p<10-5) SNPs - emphasizes the inflammatory response and related 157 
immune mechanisms, which have long been studied as risk factors for lung cancer (Takahashi, 158 
Ogata, Nishigaki, Broide, & Karin, 2010; Walser et al., 2008). We take this approach because of 159 
a pressing and unmet need to more clearly explain significant results from the recent CANTOS 160 
clinical trial. In this trial (P. M. Ridker et al., 2017), patients treated with 300 mg of 161 
canakinumab, an IL-1β inhibitor, demonstrated a large decrease in lung cancer incidence (hazard 162 
ratio=0.33, p<0.0001) and mortality (hazard ratio=0.23, p=0.0002) during median follow-up of 163 
3.7 years, one of the first such successes when targeting IL-1β in randomized human trials for 164 
lung cancer. CANTOS was primarily designed to evaluate cardiovascular outcomes and also 165 
demonstrated a significant reduction in risk of recurrent cardiovascular events (Paul M Ridker et 166 
al., 2017). It is of great interest to understand the genetic underpinnings of inflammatory- and 167 
immune-based risk in SCC to, for example, provide a more direct view into the biological 168 
mechanisms underlying disease, suggest possible therapeutic targets, or guide more accurate risk 169 
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screening policies, all goals difficult to achieve through association studies alone (Karczewski & 170 
Snyder, 2018). The main objective of our manuscript is to move toward these goals by 171 
identifying and characterizing translationally relevant SNPs that can be prioritized for functional 172 
follow-up studies. Accomplishing this objective can conserve many resources that would be 173 
needed to validate the tens of thousands of variants identified through GWAS alone, as 174 
prioritization can allow researchers to focus on a subset of GWAS variants that are likely to 175 
possess functional roles. 176 
 177 
This synthesis of the multi-faceted variant functional annotation data highlights the roles of 178 
many SNPs in genes belonging to intricate regulatory networks that affect cytokine signaling 179 
cascades and the immune response. For example, we prioritize a number of regulatory SNPs in 180 
nuclear factor-κB (NF-κB) signaling pathway genes. We also uncover a number of variants in 181 
the HLA region that may perturb disease risk through disruption of standard antigen presenting 182 
processes. Comparisons with risk variants in other lung cancer subtypes suggest that the sets of 183 
genetic variants driving inflammation risk in these diseases differ from those highlighted in our 184 
analysis of SCC. Taken together, our results help explain the CANTOS findings at a genetic 185 
level, advance understanding of the inflammation and immune related systems driving lung 186 
cancer risk across different histologies, and demonstrate how to integrate varied sources of multi-187 
omic variant annotation data in a coherent statistical framework. 188 
 189 
2 Materials and Methods 190 
2.1 Multi-dimensional annotation class estimation  191 
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To interrogate the mechanistic roles of individual variants, we utilized a Multi-dimensional 192 
Annotation Class Integrative Estimator (MACIE) (Li, 2020; Yung, 2016) that modeled a SNP’s 193 
annotation values using a generalized linear mixed model in which the annotation values were 194 
assumed to depend on a SNP’s membership in multiple latent binary classes. In the MACIE 195 
framework, function was defined as a composite of these unobserved classes, with each class 196 
designed to summarize the functionality described by a different set of annotations. This 197 
distinctive formulation of functionality as a set of multiple characteristics allowed for a more 198 
versatile and more interpretable model than was possible when considering only a single holistic 199 
score. Existing integrative methods that produce one-dimensional ratings often either sacrifice 200 
data to focus on a single attribute or sacrifice specificity to incorporate more annotations 201 
(Supplementary Figure S1). 202 
 203 
The model-fitting procedure estimated latent variant functional classes in the GLMM setting, 204 
while accounting for correlations between multiple annotations using random effects, under 205 
previously specified models for this framework (Sammel, Ryan, & Legler, 1997). Estimation 206 
proceeded with the EM algorithm, and computation of MACIE occurred in two main stages. In 207 
the training stage, the MACIE model was constructed using functional scores (36 for noncoding 208 
and synonymous variants and 12 for nonsynonymous coding variants) from a properly selected 209 
training dataset. This step obtained the fitted model parameters. In the prediction stage, the fitted 210 
model parameters were applied to a new set of SNPs to calculate the probability that each SNP 211 
belonged to a specific functional category given the data (see Appendix A for technical details). 212 
The functionality of a noncoding or synonymous coding SNP was defined with a regulatory class 213 
and an evolutionarily conserved function class. The membership of a SNP in each class was 214 
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denoted by a binary indicator, and as such, the MACIE score was a composite measure 215 
corresponding to the probability that a SNP belonged to each of the 2 × 2 = 4 possible classes. 216 
Marginal probabilities for either the regulatory or conserved classes could also be calculated by 217 
summing the two probabilities corresponding to that class. 218 
 219 
Functional annotation scores were selected and partitioned into three groups (regulatory function, 220 
evolutionarily conserved function, damaging protein function) based on previous experience 221 
(Yung, 2016) with modeling the annotations most likely to add novel and useful information in 222 
predicting functional roles. Different scores and different partitions could additionally be used 223 
for different phenotypes; such a step would require the model to be retrained. All precomputed 224 
scores for the specific MACIE model used in this analysis are available online (see Data 225 
Availability Statement).  226 
 227 
All 40 scores used in the model were downloaded from the EIGEN (Ionita-Laza, McCallum, Xu, 228 
& Buxbaum, 2016) and CADD (Kircher et al., 2014) databases. Missing values were imputed as 229 
described in the original databases. As with EIGEN (Ionita-Laza et al., 2016), we retrieved each 230 
variant’s functional class from the CADD database and grouped “Regulatory”, “Intronic”, 231 
“Downstream”, “Upstream”, “Noncoding change”, “3prime UTR”, “5prime UTR”, “Intergenic”, 232 
and “Synonymous” SNPs all in the same noncoding and synonymous variants group. The 233 
MACIE training dataset for these variants consisted of 10% of variants randomly selected from 234 
the 1000 Genomes Project data set (excluding those in dbNSFP) that were located within 500 bp 235 
upstream of a gene start site.  236 
 237 
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For each variant, the conserved class integrated eight evolutionary conservation scores 238 
downloaded from the EIGEN database: GERP_NR, GERP_RS, PhyloPri, PhyloPla, PhyloVer, 239 
PhastPri, PhastPla, and PhastVer (names given as they appear in EIGEN). These scores 240 
corresponded to outputs from the GERP++, phyloP, and phastCons algorithms and were 241 
previously described (Davydov et al., 2010; Ionita-Laza et al., 2016; Pollard, Hubisz, 242 
Rosenbloom, & Siepel, 2010; Siepel et al., 2005). The transcription regulatory class integrated 243 
28 functional scores from the CADD database (Kircher et al., 2014), including GC, CpG, 244 
ENCODE histone modification marks (EncH3K27Ac, EncH3K4Me1, EncH3K4Me3), 245 
ENCODE open chromatin marks (EncExp, EncOCCombPVal, EncOCDNasePVal, 246 
EncOCFairePVal, EncOCpolIIPVal, EncOCctcfPVal, EncOCmycPVal, EncOCDNaseSig, 247 
EncOCFaireSig, EncOCpolIISig, EncOCctcfSig, EncOCmycSig), ENCODE transcription factor 248 
binding sites data (TFBS, TFBSPeaks, TFBSPeaksMax), ChromHMM states collapsed into 5 249 
groups (cHmmTSS, cHmmTx, cHmmEnh, cHmmZnf, cHmmRepr), bStatistic, minDistTSS, and 250 
minDistTSE (all names as they appear in the CADD database). The MACIE GLMM for 251 
noncoding and synonymous SNPs was then fit by jointly integrating all 36 functional scores in 252 
two classes.  253 
 254 
For the nonsynonymous model, the training set used 10% of variants in the dbNSFP database 255 
(Liu, Wu, Li, & Boerwinkle, 2016), excluding sex chromosomes. The same eight conservation 256 
scores as above were used to evaluate an evolutionarily conserved class, and then four protein 257 
function scores (SIFT (Ng & Henikoff, 2003), PolyPhenDiv (Adzhubei et al., 2010), 258 
PolyPhenVar, and Mutation Assessor (Reva, Antipin, & Sander, 2011)) were extracted from the 259 
EIGEN database and used to predict a second class assessing the damaging function of coding 260 
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substitutions. The MACIE marginal probabilities were then calculated using the same procedures 261 
described for noncoding variants. 262 
 263 
2.2 Gene-based association analysis  264 
To focus the analysis on inflammatory- and immune-related processes, we first performed gene-265 
level inference on the largest existing lung cancer GWAS dataset. While MACIE results were 266 
calculated for all ILCCO SNPs, a key feature of the model was interpretability of the predicted 267 
classes, and so to most clearly demonstrate this advantage we concentrated discussion on those 268 
SNPs located near inflammatory- and immune-related genes. SNPs that were not located near 269 
genes but still predicted to belong to MACIE functional classes were interesting in their own 270 
right, although we left their exploration for future work. 271 
 272 
Collection and preparation of the complete ILCCO OncoArray dataset was described previously 273 
(McKay et al., 2017), and from this overall compendium we restricted our initial gene-based 274 
association analysis to a subset of 7,426 squamous cell carcinoma cases and 55,630 controls, all 275 
of European descent. We mapped (Aken et al., 2016; Chang et al., 2015) individual SNP test 276 
statistics to genes if they fell inside or within 5 kb of the gene. 277 
 278 
Gene-based inference was conducted with the Generalized Berk-Jones (GBJ) statistic (Sun & 279 
Lin, 2019). GBJ was derived from the Berk-Jones statistic, which demonstrates certain 280 
asymptotic optimality properties in set-based testing situations, and GBJ was previously shown 281 
to provide more power than comparable methods such as the Sequence Kernel Association Test 282 
(Wu et al., 2011) over a variety of commonly-occurring testing situations.   283 
 14 
 284 
All summary statistics used were derived from SNPs with a minor allele frequency greater than 285 
1% in the 1000 Genomes European cohort, thus the normality assumption of GBJ was likely to 286 
be satisfied, given the very large sample size. For very large genes comprising more than 1,000 287 
SNPs, we pruned the set to remove SNPs that were correlated at r2>0.5 (Chang et al., 2015). 288 
Each different histology was tested with the ILCCO summary statistics corresponding to that 289 
histology.   290 
 291 
In searching for functional SNPs conferring risk of SCC, we also limited our main analysis to 292 
variants possessing a marginal association of p<5 × 10() or uncommon and rare variants (minor 293 
allele frequency less than 5%) demonstrating p<5 × 10(*. The common threshold of 294 
5 × 10(+	used for genome-wide significance was not employed both because this was not a 295 
hypothesis testing study and because highly functional SNPs may demonstrate only modest 296 
association due to the limitations of marginal models. A less stringent measure was used for 297 
uncommon and rare variants because they are widely believed to demonstrate more functionality. 298 
 299 
2.3 Fine-mapping of HLA  300 
Many variants in the HLA region showed both highly significant p-values and high MACIE 301 
predictions, and the density of strongly associated SNPs was much larger compared to other 302 
portions of the genome. Thus, we first performed additional imputation and fine-mapping to 303 
discover independent association signals amidst the strong long-range LD of this region. 304 
The original genotypes were imputed using 1000 Genomes Project data (1000 Genomes Project 305 
Consortium, 2015), but larger and richer datasets have been made available since then. We 306 
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utilized the SNP2HLA (Jia et al., 2013) software to reimpute data from the original OncoArray 307 
chip with a reference dataset from the Type I Diabetes Genetics Consortium (Rich & 308 
Concannon, 2015). We then followed previous lung cancer association studies (Ferreiro-Iglesias 309 
et al., 2018) by taking a forward stepwise regression approach with all original ILCCO SNPs as 310 
well as newly imputed SNPs to help determine the strongest independent signals in the highly 311 
polymorphic region.  312 
 313 
3 Results 314 
3.1 SCC-associated genes 315 
Gene-based inference uncovered 243 genes (Supplementary Table S1) significantly associated 316 
with lung cancer risk at the Bonferroni-corrected level of p=1. 96 × 10() (Figure 1a-c), with a 317 
number of the most highly associated genes mapping to regions of the genome that were 318 
validated in previous lung cancer studies (IREB2, CHRNA5, ADAMTS7, and others) (Bosse & 319 
Amos, 2018; Timofeeva et al., 2012). Of the 243 significant genes, 187 (77%) fell inside or 320 
within 2 Mb of the HLA complex (Supplementary Figure S2). Notably, many significant genes 321 
comprised important components of NF-κB signaling pathways. Examples included TNF, 322 
CHUK, NFKBIL1, and TRIM38. Multiple major histocompatibility complex (MHC) class I and 323 
class II genes were implicated as well, including HLA-A, HLA-DQA1, and HLA-DQB1. These 324 
inflammation and immune-related loci guided our search for functional variants.  325 
 326 
3.2 Model-highlighted variants 327 
In total, we found 868 SNPs meeting the marginal association threshold (see Materials and 328 
Methods) that were predicted to belong to the regulatory class with probability greater than 0.9 329 
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(Figure 1d), and we found 65 SNPs meeting the marginal association threshold that were 330 
predicted to belong to the evolutionarily conserved class with probability greater than 0.9 (Figure 331 
1e). While some SNPs highlighted by the model possessed extremely significant p-values, the 332 
range of marginal association was also quite large (Supplementary Table S2-S5). SNPs with 333 
MACIE predictions close to one generally possessed many elevated functional scores (Figure 2-334 
3), while variants with low predictions were often characterized by less remarkable annotation 335 
values. In the following, we highlight some of the strongest model predictions to show how 336 
results can supplement previous literature and existing work in a novel and efficient manner. 337 
 338 
3.3 Variants near genes involved in NF-κB signaling  339 
The NF-κB family possesses a number of different roles in the immune response and other 340 
biological processes (Zhang, Lenardo, & Baltimore, 2017), and regulation of NF-κB has been 341 
implicated in a wide variety of inflammation-based diseases, including many cancers (Hoesel & 342 
Schmid, 2013; Lawrence, 2009; Pikarsky et al., 2004). In their inactive state, NF-κB proteins are 343 
bound to the inhibitors of NF-κB (IκB) family (Dolcet, Llobet, Pallares, & Matias-Guiu, 2005). 344 
Activation can occur through the IκB kinase (IKK) complex (Karin & Greten, 2005). 345 
 346 
TNF superfamily activation is an inducer of NF-κB signaling (Aggarwal, 2003) and is also one 347 
of the pathways that can be blocked by canakinumab-induced inhibition of IL-1β (Taniguchi & 348 
Karin, 2018). Members of the family including TNF, LTA, and LTB were three neighboring 349 
genes highly associated with SCC (all with gene-level p<1 × 10(01 for association with SCC), 350 
highlighting a link that has been observed in other inflammatory phenotypes as well (Dretzke et 351 
al., 2011; Van Schouwenburg, Rispens, & Wolbink, 2013). Two of the most significant SNPs in 352 
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the region were rs1800629 and rs1800628, found less than 1 kb upstream and downstream of the 353 
TNF transcription start and end sites, respectively. 354 
 355 
Based on data from 28 different measures of epigenetic activity, the regulatory class prediction 356 
for rs1800629 was greater than 99% (Table 1). This estimate was driven by many elevated 357 
annotation scores including, for example, ENCODE experiments demonstrating evidence of 358 
open chromatin (Figure 2f). The variant rs1800629 was previously cataloged in curated sources 359 
such as ClinVar (Landrum et al., 2014), has been referred to in the literature as TNF-308A, and 360 
has seen its adenine substitution repeatedly associated with increased expression of TNF 361 
(Karimi, Goldie, Cruickshank, Moses, & Abraham, 2009; Mira et al., 1999).  Consistent with the 362 
CANTOS hypothesis that inflammation contributes to lung cancer risk, the adenine minor allele 363 
was risk-conferring for SCC (OR=1.16, p=1.66 × 10(+), indicating the possibility that 364 
rs1800629 was linked with SCC because it increased TNF expression and thus also inflammatory 365 
activity. 366 
 367 
Although rs1800628 (OR=1.28, p=1.54 × 10(02) demonstrated a level of marginal association 368 
that was multiple orders of magnitude more significant than its upstream counterpart rs1800629, 369 
the MACIE prediction was less than 0.01 for both classes (Table 1) due to a lack of regulatory 370 
and evolutionary conservation evidence (Figure 2-3) among the available data. The disparity in 371 
p-values was possibly due to the limitations of marginal regressions, for example, rs1800628 372 
may have fallen in strong linkage disequilibrium with another important SNP. rs1800628 may 373 




As a subunit of the IKK complex, CHUK (gene-level p=1.60 × 10() for association with SCC) 377 
was another key member of the NF-κB signaling cascade (Hacker & Karin, 2006) determined to 378 
be significantly associated with lung cancer risk. Although no SNPs in CHUK reached the 379 
standard genome-wide significance level of 5 × 10(+, the combination of 26 SNPs with p-values 380 
less than 5 × 10() pushed the gene-level association between CHUK and SCC to significance. 381 
Integrated annotation analysis (Supplementary Figure S3) suggested the signal originated in part 382 
from rs28372851 (OR=1.25, p=5.18 × 10(4), a variant located approximately 2 kb upstream of 383 
the transcription start site. This SNP was previously predicted (Fishilevich et al., 2017) to lie in 384 
an enhancer region of CHUK, and the combined data strongly estimated that rs28372851 385 
belonged to the regulatory class, with a prediction score greater than 0.99 (probability conserved 386 
class less than 0.1%). The MACIE regulatory prediction was driven by multiple epigenetic 387 
features including high histone modification signal peaks (Supplementary Figure S3b-c). 388 
Increased expression of CHUK can further activate NF-κB (Hacker & Karin, 2006).  389 
 390 
3.4 Variants near inhibitors of NF-κB signaling 391 
The CANTOS trial illustrated that an IL-1β inhibitor could provide significant therapeutic 392 
benefits in lung cancer, so it followed that searching for genetic variation mimicking the function 393 
of canakinumab might also uncover SNPs with key protective roles. One such example was 394 
identified in TRIM38 (gene-level p=1.26 × 10(01), which was previously observed to inhibit 395 
cytokines, including TNF and IL-1β, that activate NF-κB (Hu & Shu, 2017). TRIM38 reached 396 
gene-level significance in association with SCC due in part to 15 genome-wide significant SNPs, 397 
although many of them fell in high LD (Supplementary Figure S4a). In particular, the SNP 398 
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rs72832596 (OR=1.21, p=2.02 × 10(5) possessed many elevated annotation values 399 
(Supplementary Figure S4b-c) that contributed to a model prediction of greater than 0.99 for 400 
inclusion in the class of regulatory SNPs (probability conserved class less than 0.1%, 401 
Supplementary Figure S4d-e). Further validation was provided by the GTEx (GTEx Consortium 402 
et al., 2013) project, which showed rs72832596 to be an eQTL of TRIM38 in whole blood, as the 403 
minor allele was associated with decreased expression of TRIM38. While GTEx discoveries 404 
suffer from the same drawbacks as other association results, rely on small sample sizes, and are 405 
not available for all SNPs with annotation data, positive eQTL findings do offer some evidence 406 
of regulatory function. The minor allele also showed an effect direction (Supplementary Figure 407 
S4f) consistent with a positive correlation between inflammation and disease risk. As immune 408 
cells may comprise a significant proportion of whole blood, the expression-increasing allele at 409 
rs72832596 could possibly be interpreted as a pseudo-dose of canakinumab increasing the level 410 
of cytokine inhibition, thus reducing the amount of signaling by IL-1β and associated proteins 411 
and leading to a decrease in inflammation.  412 
 413 
A final highly significant gene in SCC with connections to cytokine regulatory networks was 414 
NFKBIL1 (gene-level p=3.04 × 10(01), which has been shown to demonstrate IκB-like 415 
functions (Chiba, Matsuzaka, et al., 2011; Hayden & Ghosh, 2012) and has been linked with, 416 
among other inflammation-related phenotypes, rheumatoid arthritis (Chiba, Miyashita, et al., 417 
2011; Okamoto et al., 2003). The integrated annotation data highlighted rs2239527 (OR=1.10, 418 
p=2.02 × 10()), a variant approximately 5 kb upstream (Supplementary Figure S5a) of 419 
NFKBIL1 that showed exceptional conservation across primates, mammals, and vertebrates with, 420 
for example, large phastCons, phyloP, and GERP++ scores. These scores and others led the 421 
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model to predict that rs2239527 belonged to both the regulatory and conserved classes with 422 
probability approaching 1 (Supplementary Figure S5b-c). Results from multiple other alternative 423 
variant scoring systems also highlighted this variant (Supplementary Figure S5d-f). 424 
 425 
3.5 HLA risk variants 426 
Although the CANTOS trial demonstrated the therapeutic benefit of targeting cytokine signaling 427 
processes, annotation data also implicated other features of inflammatory and immune responses 428 
in conferring lung cancer risk. In particular, we previously noted that many of the most 429 
significant SNPs and genes associated with SCC fell in the HLA region.  More specifically, 430 
variants in HLA genes prioritized by the MACIE model (Figure 4a-b) demonstrated a variety of 431 
links to the dysregulated immune response that has been observed in lung cancers (Carbone, 432 
Gandara, Antonia, Zielinski, & Paz-Ares, 2015; Gandhi et al., 2018; Palucka & Banchereau, 433 
2012). 434 
 435 
Re-imputation and fine-mapping in the HLA selected two independent association signals amidst 436 
the strong long-range LD of the HLA (Supplementary Table S6). The association and prediction 437 
models converged for HLA-DQB1 variant rs1049133 (unconditional OR=1.18, p=3.45 × 10-8), 438 
which ranked as the second strongest independent association signal in the entire HLA and was 439 
predicted by the available annotation data to belong to the conserved class with probability 440 
93.4%. HLA-DQB1 (gene-level p=4.10 × 10-10) was significantly associated with SCC risk, and 441 
the protein is a receptor found on antigen-presenting cells. In contrast, the most significant SNP 442 
in the reimputation, rs3094604, did not show an annotation profile indicating that it belonged to 443 
one of the model classes (Table 1). Thus, this example again succinctly demonstrated the added 444 
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information generated by modeling annotation data. HLA-DQB1 was also notable for its status as 445 
the gene with the second largest number of SNPs both passing the marginal association threshold 446 
and possessing a MACIE regulatory prediction of greater than 0.9, with 35 such SNPs. HLA-447 
DQA1 (gene-level p<1 × 10(01) held the most such SNPs with 86, and no other MHC-region 448 
gene held more than 11.  449 
 450 
Additionally, many of the model-prioritized SNPs located outside HLA-DQB1 and HLA-DQA1 451 
still showed strong links to these genes. Across all chromosomes there were only 868 SNPs 452 
passing the marginal association threshold and possessing a MACIE regulatory prediction of 453 
greater than 0.9, with 613 (71%) falling in the HLA region. Of these 613, 21% were eQTLs of 454 
HLA-DQA1 in one or both of blood or lung tissue according to GTEx, and 29% were eQTLs of 455 
HLA-DQB1 in one or both of blood or lung tissue according to GTEx (Supplementary Table S7), 456 
for a total of 562 eQTL findings across both tissues. Of the 562 SNP-expression pairs, over 99% 457 
of the effect directions were oriented such that the expression-lowering allele corresponded to 458 
the same allele associated with a marginal increase in SCC risk. The abundance of highly 459 
associated and model-prioritized SNPs that were previously validated as HLA eQTLs in blood 460 
and lung tissue suggested that many SNPs may contribute to SCC risk by modulating expression 461 
of MHC genes. 462 
 463 
Many of the significantly associated SNPs in the HLA region were nonsynonymous coding 464 
SNPs, and for these variants we calculated a damaging protein substitution class instead of the 465 
regulatory class (see Materials and Methods). In general, highly linked nonsynonymous variants 466 
tended to demonstrate more variation in conservation class predictions. For example, in HLA-467 
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DQA1 the missense variants rs707949 (OR=1.17, p=1.61 × 10(07) and rs707962 (OR=1.18, 468 
p=1.23 × 10(07), demonstrated correlation falling just below 1. However (Figure 4c-f), 469 
rs707949 earned a higher evolutionarily conserved class prediction of 0.85 compared to 0.12 for 470 
rs707962. As with all previous predictions, results should be interpreted with caution as some 471 
functionality of nonsynonymous SNPs – for example, their potential to influence the folding of 472 
HLA-DQA1 - are roles not directly covered by existing classes in the MACIE model and 473 
demonstrate the potential for MACIE modeling of additional attributes once more annotations 474 
are available to predict other categories.  475 
 476 
3.6 Significantly associated genes in other histologies 477 
Previous reports have described the genetic bases of different lung cancer histologies as highly 478 
dissimilar (Wang et al., 2015); thus, important variants may differ and therapeutic strategies such 479 
as those used in CANTOS may see efficacy vary by subtype. To investigate whether the variants 480 
highlighted above may also contribute to risk of other lung cancer subtypes, we reperformed the 481 
initial step of our investigation by conducting separate gene-level analyses with the ILCCO 482 
adenocarcinoma and small cell lung cancer cases. Consistent with previous reports, we found 483 
that the top genes associated with SCC showed little overlap with the other two histologies. 484 
Compared to the 243 genes significant at the Bonferroni-corrected significance level in SCC, 485 
only 39 genes reached significance in adenocarcinoma (Fig 1b), even with a larger number of 486 
adenocarcinoma cases (11,270 compared to 7,426 for SCC). In particular, the inflammation-487 
related genes TNF, CHUK, TRIM38, and NFKBIL1 did not rank among the top 2,000 most 488 
significant genes, and no HLA genes passed the Bonferroni-corrected significance level. This 489 
difference could partly be attributable to the increased mutation burden associated with 490 
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squamous cell carcinoma of the lung. Small cell lung cancer showed even fewer significant 491 
genes (Figure 1c) with only 12 passing the Bonferroni threshold, although this low number was 492 
likely also impacted by the reduced sample size of 2,170 small cell lung cancer cases. Marginal 493 
association strength for previously mentioned SNPs also varied across histology (Supplementary 494 
Table S8). 495 
 496 
As we previously detailed, association results are limited in scope and interpretation. However, 497 
by demonstrating the differences in significant genes between SCC and other histologies, we 498 
showed that a similar integrated analysis of adenocarcinoma or small cell lung cancer would 499 
likely identify many distinct variants.  500 
  501 
4 Discussion 502 
Genetic studies of lung cancer have often focused on extracting information from association 503 
analyses using only a few types of data. Yet, for such studies to further disentangle the disease’s 504 
complex genetic etiology and provide more translational value, it is becoming increasingly 505 
important to integrate and utilize the full scope of available omics information, recorded from a 506 
wide range of experimental modalities (Freedman et al., 2011; Karczewski & Snyder, 2018). We 507 
attempted to advance this objective and refine results from the recent CANTOS clinical trial by 508 
harnessing a variety of diverse genomic datasets to elucidate how genetic variants identified 509 
through GWAS may confer lung SCC risk through inflammation and immune networks.  510 
 511 
Our analysis identified hundreds of SNPs that demonstrate evidence of association with SCC and 512 
possessed a greater than 90% chance of inclusion in at least one of three classes: regulatory, 513 
 24 
evolutionarily conserved, and protein damaging. These variants represented a filtration of the 514 
tens of thousands of highly associated SNPs documented in the largest existing lung cancer 515 
GWAS, which, for example, reported a table of over 21,000 highly associated SNPs. Our results 516 
demonstrated that the most significant variants at GWAS risk loci may not necessarily be 517 
functional SNPs (Supplementary Table 9), and hence it may not be desirable to simply select the 518 
most significant variants for follow-up studies. By leveraging functional annotation information, 519 
we showed that it is possible to select a much smaller subset of significantly associated SNPs for 520 
follow-up. Such work can reduce the number of variants prioritized for additional studies by over 521 
an order of magnitude and can translate to large cost and effort savings. In addition, our work 522 
markedly contributed to knowledge about the functional mechanisms at each identified risk 523 
locus, providing further quantitative and qualitative insight about how individual variants possess 524 
roles in the major biological themes leading to lung cancer risk. We next summarize some of 525 
these broader findings regarding risk factors for lung cancer. 526 
 527 
In further analyzing SNPs selected by the integrative annotation analysis, we found indications 528 
that the NF-κB inflammation signaling pathway and HLA-mediated immune responses were key 529 
mechanisms in SCC disease progression. Specifically, multi-omics data from dozens of diverse 530 
sources demonstrated that a number of annotation-prioritized SNPs were located near genes 531 
involved in regulation of NF-κB activation and antigen presentation. Although our study is not 532 
the first to link lung cancer with inflammation, NF-κB (Ben-Neriah & Karin, 2011; Taniguchi & 533 
Karin, 2018), or the HLA region (Ferreiro-Iglesias et al., 2018), to our knowledge, it is among 534 
the first attempts to integrate genome-wide functional annotation data with large-scale lung 535 
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cancer GWAS findings in pinpointing relevant variants and explaining the specific roles of these 536 
substitutions.  537 
 538 
The abundance of variants highlighted in this report reinforces the view that lung cancer boasts a 539 
highly complex genetic etiology, with large networks of SNPs possessing non-trivial amounts of 540 
important behavior. Thus, as a complement to the traditional GWAS individual SNP association 541 
analysis, the novel approach outlined in this paper – identifying significant genes through set-542 
based inference and leveraging rich external annotation data to assess the roles of significant 543 
SNPs in these genes – could likely be applied to search for genetic determinants of lung cancer 544 
risk in other biological systems as well. We emphasize that MACIE offers an unsupervised and 545 
highly interpretable tool allowing researchers to move beyond the conventional search for 546 
associations and instead determine the biological consequences of genetic variation. When 547 
applying the method to different traits, researchers should leverage disease-specific biological 548 
knowledge and should ensure that the classes and functional annotations used are relevant for the 549 
outcome of interest. 550 
 551 
Our manuscript focused on squamous cell carcinoma because the vast majority of ILCCO SCC 552 
cases identified as current or past smokers; these subjects likely demonstrated a larger mutation 553 
burden and increased pulmonary inflammation due to tobacco smoke (Spitz et al., 2011), and 554 
therefore we expected inflammatory mechanisms to display a more direct connection with SCC 555 
than other lung cancer subtypes. Comparisons of SCC GWAS results with adenocarcinoma and 556 
small cell lung cancer revealed largely disparate profiles of genetically-induced inflammation 557 
risk. Hence our findings illustrated the importance of studying disease subtypes and considering 558 
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differing underlying biological mechanisms when utilizing IL-1β inhibitors as a strategy for 559 
treating or preventing lung cancer.  560 
 561 
The specific findings discussed in this manuscript offer many avenues for follow-up research. 562 
The profusion of functional SNPs indicates that more precise interventions tailored to each 563 
patient’s individual genome may be more successful than wide-ranging therapies aimed at the 564 
general population. Integrative investigations of other processes critical to lung cancer 565 
progression will be essential as well. Further experimental validation will also be necessary to 566 
continue refining the performance of data-driven predictions and provide additional evidence 567 
linking specific variants to disease.  568 
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Figure Captions 776 
Figure 1. Gene-level Manhattan plots for association with lung cancer and SNP-level Manhattan 777 
plots marked with MACIE predictions. a, Gene-level Manhattan plot for lung squamous cell 778 
carcinoma. Each point represents one gene. All genes passing the Bonferroni-corrected threshold 779 
are colored black (even chromosomes) or red (odd chromosomes), with non-significant genes 780 
shown in grey. Labeled numbers note count of significant genes on each chromosome (see 781 
Supplementary Table S1 for list of all significant genes). The majority of significant SCC genes 782 
fall on chromosome 6. b-c, Gene-level Manhattan plot comparing significant squamous cell 783 
carcinoma genes against significant genes in (b) adenocarcinoma and (c) small cell carcinoma. 784 
Color corresponds to whether the gene is significant in just one disease or both. Only genes 785 
passing the Bonferroni-corrected significance threshold are displayed. d-e, SNP-level Manhattan 786 
plot for association with lung cancer where the points are additionally colored according to the 787 
MACIE prediction of inclusion in the (d) regulatory class and (e) conserved class. Labeled 788 
numbers note count of significant genes on top six chromosomes with most SNPs passing the 789 
marginal association threshold (see Materials and Methods) and possessing a MACIE regulatory 790 
prediction greater than 0.9 as well as top three chromosomes with most SNPs passing the 791 
marginal association threshold and possessing a MACIE conserved prediction greater than 0.9. 792 
 793 
Figure 2. Highly-weighted annotation scores used to calculate MACIE probability of regulatory 794 
class in noncoding SNPs. a-f, Highly-weighted (see Supplementary Figure S1 for weights) 795 
regulatory annotation scores for SNPs associated with the inflammatory and immune responses, 796 
including (a) logarithm of peak H3K27Ac signal, (b) logarithm of peak H3K4Me1 signal, (c) 797 
peak RNA polymerase II signal, (d) logarithm of distance to closest transcription start site, (e) 798 
 34 
logarithm of number of ChIP transcription factor binding site peaks across all cell types and 799 
tissues, and (f) peak DNase I signal, all in ENCODE data. Dashed black line denotes an 800 
empirical cumulative distribution function for the measure on the x-axis, i.e. the (x,y) position of 801 
a point on the line illustrates that a variant scoring x on the given annotation has a value that is 802 
greater than y percent (where y is measured according the secondary y-axis on the right) of all 803 
variants passing the threshold for marginal association (see Materials and Methods) with SCC 804 
(SNPs not discussed are shaded in gray). If a line drawn straight up from the x-axis through a 805 
SNP intersects the black line at a value near 1, then that SNP possesses an annotation value 806 
greater than most other SNPs demonstrating evidence of association with SCC. The x-axis shows 807 
at least the second through ninety-eighth percentile for all annotations. All SNPs mentioned in 808 
main text are plotted for completeness, including missense SNPs that are not evaluated using 809 
regulatory annotations. Discussed gene is given in parentheses next to each SNP, although a 810 
single SNP may be proximal to multiple genes. Not all SNPs possess a value for all annotations; 811 
missing values are not plotted but are imputed as described in the original data sources (see 812 
Materials and Methods). While SNPs predicted by MACIE as belonging to the regulatory class 813 
do not always show the lowest p-values or most extreme scores, they possess an annotation 814 
profile containing multiple notable measures that cumulatively contribute to a significant 815 
MACIE prediction. SNPs with low regulatory predictions may demonstrate one or a few large 816 
scores, but their overall annotation profile for this class consists of mostly unremarkable values. 817 
 818 
Figure 3. Highly-weighted annotation scores used to calculate MACIE probability of 819 
evolutionarily conserved class. a-f, Highly-weighted (see Supplementary Figure S1 for weights) 820 
conservation annotation scores for SNPs associated with the immune and inflammatory 821 
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responses, including (a) GERP++ rejected substitution score, (b) phastCons primate score, (c), 822 
phastCons placental mammal score, (d) phyloP placental mammal score, (e) phastCons 823 
vertebrate score, and (f) phyloP vertebrate score, all plotted against marginal P-value for 824 
association with SCC. Dashed black line denotes an empirical cumulative distribution function 825 
for the measure on the x-axis. The x-axis shows at least the second through ninety-eighth 826 
percentile for all annotations. While SNPs predicted by MACIE as belonging to the conserved 827 
class do not always show the lowest p-values or most extreme scores, they possess an annotation 828 
profile containing multiple elevated measures that cumulatively contribute to a significant 829 
MACIE prediction.  830 
 831 
Figure 4.  MHC region MACIE scores as well as annotation scores and comprehensive variant 832 
scores for HLA-DQA1 SNPs. a-b, MACIE regulatory (a) and conserved class (b) scores plotted 833 
against p-value for MHC SNPs. SNPs are colored according to their score for the complementary 834 
class, i.e. when the regulatory score is on the y-axis, the color corresponds to the conservation 835 
score, and when the conservation score is on the y-axis, the color corresponds to either the 836 
damaging protein function score (for nonsynonymous SNPs) or regulatory score (other SNPs). A 837 
very small p-value is not necessarily indicative of a high MACIE prediction. c-e, Individual SNP 838 
annotation scores and comprehensive ratings for significant SNPs in HLA-DQA1 including (c) 839 
GERP++ rejected substitutions score, (d) phastCons vertebrate score, (e) CADD PHRED 840 
comprehensive score (higher indicates more deleterious), and (f) SIFT protein score (lower 841 
indicates more deleterious) plotted against P -value. We only show those SNPs passing the 842 
marginal association threshold with SCC (see Materials and Methods). Black dashed line shows 843 
the empirical distribution of these measures (using secondary y-axis on right side of plots) for all 844 
 36 
SNPs across the genome meeting this significance threshold. Variants are colored as described in 845 
EIGEN. 846 
 37 
Appendix A: Fitting the MACIE Model 847 
Suppose for a noncoding or synonymous SNP 9 and annotation class :	(: = 1,2)  we observe a 848 
set >?@ = AB?@0, … , B?@DEF of G@ different functional scores. Let H? = (I?0, I?1) denote the vector 849 
of unobserved latent functional binary class indicators, with I?0	a binary indicator for SNP 850 
9		possessing regulatory function and I?1 a binary indicator for SNP 9	 possessing evolutionarily 851 
conserved function. Then for : = 1,2 and J = 1,… , G@, the functional scores B?@K  are modeled 852 
using a GLMM that assumes their means L?@K = M(B?@K) are linear functions of the latent binary 853 
functional status indicators I?@ and the random effects N?@K . Specifically, we assume  854 
O@KPL?@KQ = R7@K + I?@R0@K + N?@K , 855 
where O@K  is a canonical link function. We set T?@ = PN?@0,⋯ , N?@KQ′ = W@X?@  with X?@ ∼856 
Z[\(0, ]) as a vector of length @̂ < @̀ to reduce computational complexity, with W@ acting as 857 
factor loadings. This step is reasonable because many functional annotations likely attempt to 858 
measure the same few underlying variables, and we assume there are @̂ of these variables. 859 
 860 
The expectation maximization algorithm is used to fit the model. The algorithm, expectation 861 
steps, and maximization steps are similar to those previously described (Sammel et al., 1997) for 862 
latent variable models with mixed discrete and continuous outcomes. Expectations that cannot be 863 
evaluated in closed form are taken with Gauss-Hermite quadrature, and score equations that 864 
cannot be solved in closed form are updated with a one-step Fisher scoring procedure (Sammel 865 
et al., 1997). Given the fitted model parameters and a new SNP 9a with corresponding annotation 866 
scores >?b0 and >?b1, the probability c(H?b = d|>?b0, >?b1) is the MACIE score, where	d =867 
(f0, f1) ∈ {0,1} × {0,1}. The same model fitting procedure is used for nonsynonymous coding 868 
 38 
SNPs, except we utilize a different set of annotations and training data (see Material and 869 
Methods). Other sets of annotations may be used to probe different functional classes as well. 870 


















































































































































































































































































● ● ●●●●●● ●●● ●●●●●● ●● ●● ●●● ● ●● ●● ●●● ●● ● ●●
●








●●● ●●● ●● ●●● ● ●● ●● ●
●


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































● ●● ●●● ●

























































































































































































































































































































































































































































































































































































































Other Sig. SNPs rs1049133 (HLA−DQB1) rs1800628 (TNF)
rs1800629 (TNF) rs2239527 (NFKBIL1) rs28372851 (CHUK)
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